β-Eudesmol Alleviates Inflammatory Injury in Septic Cardiomyopathy Through Enhancing GSK3B Activity to Inhibiting...

Area of Science:

• Biochemistry
• Pharmacology
• Cardiology

Background:

• Septic cardiomyopathy (SCM) is a critical complication of sepsis, characterized by excessive inflammation and cardiac dysfunction.
• Beta-eudesmol, a natural sesquiterpene alcohol, exhibits anti-inflammatory properties, but its role in SCM is not well understood.

Purpose of the Study:

• To investigate the therapeutic effects of beta-eudesmol on SCM.
• To elucidate the underlying molecular mechanisms of beta-eudesmol in mitigating SCM-induced myocardial injury.

Main Methods:

• Established a rat model of SCM using cecal ligation and puncture (CLP).
• Assessed cardiac function markers (BNP, cTnI) via ELISA.
• Evaluated myocardial tissue damage using HE and TUNEL staining.
• Quantified gene and protein expression (RT-qPCR, Western blotting) including inflammatory cytokines and GSK3B pathway components.

Main Results:

• Beta-eudesmol treatment significantly reduced serum BNP and cTnI levels, indicating improved cardiac function.
• It decreased pro-inflammatory cytokines (IL-6, IL-1β, TNF-α, LPS) and IL-17 levels in SCM rats.
• Beta-eudesmol inhibited myocardial apoptosis and inflammatory cell infiltration.
• The compound enhanced GSK3B activity by reducing its phosphorylation, thereby suppressing IL-17A, CXCL1, CXCL2, and CCL20 expression.

Conclusions:

• Beta-eudesmol effectively alleviates myocardial inflammation and apoptosis in a rat model of septic cardiomyopathy.
• The therapeutic effect is mediated by the inhibition of IL-17-driven chemokine expression through enhanced GSK3B activity.
• Beta-eudesmol presents a promising therapeutic candidate for managing septic cardiomyopathy.